[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340611-105":59,"doc-detail-340611-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bladder-cancer-biomarkers-current-approaches-and-future-directions","Bladder cancer biomarkers: current approaches and future directions","","Bladder cancer presents a major global health challenge requiring reliable diagnosis and monitoring. Biomarkers are central to early detection, prognosis, and therapy guidance, and this review synthesizes the current biomarker landscape, highlighting FDA-approved urinary molecular tests and promising emerging candidates. Limitations in sensitivity and specificity—especially in early-stage disease—along with variable sample collection and non-standardized isolation methods contribute to inconsistent performance across studies. Continued efforts are needed to standardize testing and validate markers in clinical practice to improve patient outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bladder-cancer-biomarkers-current-approaches-and-future-directions/340611/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bladder-cancer-biomarkers-current-approaches-and-future-directions/340611.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are biomarkers important in bladder cancer management?","Question",{"text":112,"@type":113},"Biomarkers support early detection, prognosis assessment, and monitoring of treatment and disease risk, helping clinicians target clinical endpoints or biological changes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations affect current FDA-approved molecular biomarkers for bladder cancer?",{"text":117,"@type":113},"Key challenges include limited sensitivity and specificity in early-stage detection and inconsistencies influenced by different sample collection and handling procedures across laboratories.",{"name":119,"@type":110,"acceptedAnswer":120},"Which emerging biomarker types are discussed in the review?",{"text":121,"@type":113},"The review highlights extracellular vesicles and exosomes as potential biomarker sources, and it also lists newly investigated markers such as UBC Rapid test/UBC ELISA, XPERT BC Monitor, BC UroMark, TaqMan Arrays, sFAS, BTF, and IGF2/MAGE-A3.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340611,1792163635,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","TYPE Review  \nPUBLISHED 29 November 2024 DOI 10.3389/fonc.2024.1453278  \nOPEN ACCESS  \nEDITED BY  \nHua Tan,  \nNational Human Genome Research Institute (NIH), United States  \nREVIEWED BY  \nHengrui Liu,  \nUniversity of Cambridge, United Kingdom Hongqi Teng,  \nUniversity of Texas MD Anderson Cancer Center, United States  \n*CORRESPONDENCE  \nFrouzandeh Mahjoubi  \n [frouz@nigeb.ac.ir](frouz@nigeb.ac.ir)  \nRECEIVED 22 June 2024  \nACCEPTED 05 November 2024  \nPUBLISHED 29 November 2024  \nCITATION  \nAhangar M, Mahjoubi F and Mowla SJ (2024) Bladder cancer biomarkers: current approaches and future directions.  \nFront. Oncol. 14:1453278 .  \ndoi: 10.3389/fonc.2024.1453278  \nCOPYRIGHT  \n© 2024 Ahangar, Mahjoubi and Mowla. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBladder cancer biomarkers: current approaches and future directions  \nMelika Ahangar 1, Frouzandeh Mahjoubi 1* and Seyed Javad Mowla 2  \n1 Department of Clinical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran, 2 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran  \nBladder cancer is a signiﬁcant health concern worldwide, necessitating effective diagnostic and monitoring strategies. Biomarkers play a crucial role in the early detection, prognosis, and treatment of this disease. This review explores the current landscape of bladder cancer biomarkers, including FDA-approved molecular biomarkers and emerging ones . FDA-approved molecular biomarkers, such as BTA stat, BTA TRAK, and NMP22, have been instrumental in diagnosing and monitoring bladder cancer. These biomarkers are derived from urinary samples and are particularly useful due to their sensitivity and speciﬁcity. As we move forward, we should continue to seek ways to optimize our processes and outcomes, these markers remain seriously challenged in the detection of early bladder cancer due to their limited sensitivity and speciﬁcity. For instance, sensitivities of BTA stat in bladder tumor detection have varied between 40-72%, while its speciﬁcities vary from 29-96% . In the same way, 70% sensitivity and 80% speciﬁcity have been recorded for BTA TRAK, while 11-85 .7% sensitivity and 77- 100% speciﬁcity have been documented for NMP22 BladderChek. The given variations, especially the low sensitivity in the diagnosis of bladder cancer at an early stage call for the invention of better diagnostic systems. Moreover, different sample collection and handling procedures applied in different laboratories further contribute to inconsistent results obtained. Extracellular vesicles (EVs) and exosomes, which carry a vast number of proteins, are being considered as potential biomarkers. Although these markers show promise, challenges remain due to non-standardized isolation techniques and lack of reproducibility across studies. Moreover, the discovery of new potential biomarkers is ongoing. For instance, the UBC® Rapid test and UBC ELISA kit, the XPERT BC Monitor, BC UroMark, TaqMan® Arrays, Soluble FAS (sFAS), Bladder tumor ﬁbronectin (BTF), and IGF2 and MAGE-A3 are among the newest biomarkers under investigation. In conclusion, while bladder cancer biomarkers have shown great promise, more research is needed to standardize the testing procedures and validate these biomarkers in a clinical setting. This will pave the way for more accurate andefﬁcient diagnosis and monitoring of bladder cancer, ultimately improving patient outcomes.  \nKEYWORDS  \nbiomarkers, diagnostic strategies, prognosis strategies, monitoring strategies, FDA approved molecu","cbCaiaug7e5R0a2I","https://ap.wps.com/l/cbCaiaug7e5R0a2I","pdf",3740966,"English","# 1 Introduction\n## Biomarker concepts and definitions\n## Literature search strategy\n## Selection criteria","[{\"question\":\"Why are biomarkers important in bladder cancer management?\",\"answer\":\"Biomarkers support early detection, prognosis assessment, and monitoring of treatment and disease risk, helping clinicians target clinical endpoints or biological changes.\"},{\"question\":\"What limitations affect current FDA-approved molecular biomarkers for bladder cancer?\",\"answer\":\"Key challenges include limited sensitivity and specificity in early-stage detection and inconsistencies influenced by different sample collection and handling procedures across laboratories.\"},{\"question\":\"Which emerging biomarker types are discussed in the review?\",\"answer\":\"The review highlights extracellular vesicles and exosomes as potential biomarker sources, and it also lists newly investigated markers such as UBC Rapid test/UBC ELISA, XPERT BC Monitor, BC UroMark, TaqMan Arrays, sFAS, BTF, and IGF2/MAGE-A3.\"}]","Bladder cancer biomarkers: current approaches and future directions | PDF",1790037674,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0670d969cc74511c8733313bbb07c913.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d82ff5ad8fbc635be6ed76f4cd3ede3.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/483ab4b283e93eb9000bcb64bc95009d.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e1d890520ffce6a325cd435674fac6c.webp",980,1385]